Twitter | Search | |
Pharmaxis
A pharmaceutical research company with approved products in world markets and a drug discovery program focused on treatments for fibrosis and inflammation.
135
Tweets
142
Following
176
Followers
Tweets
Pharmaxis Dec 12
Pharmaxis reveals first sales of Aridol® in US following successful relaunch via
Reply Retweet Like
Pharmaxis Dec 12
An asthma diagnostic developed by notches up first distributor sales in the USA.
Reply Retweet Like
Pharmaxis retweeted
Proactive Investors Nov 22
Pharmaxis advancing partnership talks for LOXL2, and increasing anti fibrotic applications via
Reply Retweet Like
Pharmaxis Nov 21
Chairman Malcolm McComas details the successful evolution of the company’s amine oxidase chemistry platform at the AGM
Reply Retweet Like
Pharmaxis Nov 20
Plenty of positive feedback from our research day presentations and lab tours. You can catch up here:
Reply Retweet Like
Pharmaxis Nov 19
Pharmaxis moving into phase I clinical trial of its small molecule LOX inhibitor via
Reply Retweet Like
Pharmaxis Nov 19
Catch up on the Investor Briefing Day by seeing vidoes of all the presentations on our website
Reply Retweet Like
Pharmaxis Nov 19
How an antifibrotic could help treat . The Garvan Institute's Thomas R Cox presents on the collaboration with Pharmaxis.
Reply Retweet Like
Pharmaxis Nov 19
Boehringer Ingelheim Project Manager Thomas Jensen presents on developments with a drug discovery at the Pharmaxis Investor Research Briefing. Full details at
Reply Retweet Like
Pharmaxis retweeted
Small Caps Nov 14
Pharmaxis (: ) takes firm steps towards commercialising suite of fibrotic disease treatments
Reply Retweet Like
Pharmaxis retweeted
Proactive Investors Nov 14
Pharmaxis receives positive results from clinical trial of treatment for fibrotic diseases via
Reply Retweet Like
Pharmaxis retweeted
The Bridge Program Oct 29
Petra Moroni-Zentgraf presenting from on regulatory approvals
Reply Retweet Like
Pharmaxis retweeted
Danny Bosch Oct 28
Reply Retweet Like
Pharmaxis retweeted
The Bridge Program Oct 28
Steering Committee member introducing Gary Phillips from with a case study on facing the early challenges and implementing a successful turnaround strategy. Very useful advice and real world examples
Reply Retweet Like
Pharmaxis Oct 25
We have one of the best early stage pipelines for a biotech company of our size says CEO Gary Phillips in the latest Quarterly Report.
Reply Retweet Like
Pharmaxis Oct 10
Pharmaxis gets another fatty liver drug through clinical trials; shares gain via
Reply Retweet Like
Pharmaxis Oct 10
Positive Phase 1 clinical trial results on anti fibrotic compound.
Reply Retweet Like
Pharmaxis Oct 9
Excellent story on the rise of fatty liver disease - a focus of Pharmaxis research.
Reply Retweet Like
Pharmaxis retweeted
Proactive Investors Sep 17
Pharmaxis adds valuable experience with Ed Rayner appointment via
Reply Retweet Like
Pharmaxis Sep 17
Biotech and investment specialist Ed Rayner adds further depth to a highly experienced Board
Reply Retweet Like